Ventripoint Diagnostics Announces Support for the Global Congenital Heart Disease Alliance

Executive Summary

• Ventripoint Diagnostics announced its support for the newly forming Global Congenital Heart Disease Alliance (GCHDA), an industry coalition dedicated to accelerating the development, commercialization, and global adoption of congenital cardiovascular technologies.
• The company will participate in GCHDA's programming, including its annual summit and innovation showcases, and collaborate on shared research and commercial initiatives.
• GCHDA plans to fund and deploy four VMS+ cardiac imaging units to expand access to advanced diagnostic care for the congenital heart disease community.

Key Details

• Ventripoint's support aligns with GCHDA's mission to build a unified ecosystem for congenital heart disease (CHD) through membership, advocacy, multi-center research, and convening platforms.
• GCHDA will assist in funding and placing 4 VMS+ cardiac imaging units to directly support patients, families, hospitals, and research teams.
• Ventripoint's flagship VMS+ platform utilizes AI to convert standard 2D echocardiograms into highly accurate 3D models of all four heart chambers, delivering cMRI-level measurement accuracy at the point of care.
• The announcement references the World Heart Federation's 2026 report, noting CHD affects ~2% of live births globally (~16 million people), with over 90% of children in lower- and middle-income countries lacking timely access to care.
• Ventripoint intends to collaborate with GCHDA members on research and commercial initiatives aimed at improving CHD care outcomes globally.

Notable Quotes

• Joe Hostetter, Director of the CHD Program at Ventripoint Diagnostics: "Congenital heart disease affects patients across every stage of life, from infancy through adulthood, and the technologies needed to diagnose and monitor these conditions require exactly the kind of collaborative ecosystem that GCHDA is working to build... Supporting GCHDA reflects our commitment to working alongside the broader CHD community to help close that gap."
• Julia Friesen, Executive Director, Global Congenital Heart Disease Alliance: "We are pleased to welcome Ventripoint as a supporter of the Global Congenital Heart Disease Alliance... As part of our initial efforts, we will assist in funding and placing 4 VMS+ cardiac imaging units to directly support the CHD community and expand access to advanced diagnostic care."